<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In accordance with the clinical and coagulographic data on 172 patients with ischemic brain <z:hpo ids='HP_0001297'>stroke</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>), the authors developed a method of the use of some medicamentous agents (<z:chebi fb="5" ids="28304">heparin</z:chebi>, platelet inhibitors, fresh-frozen blood plasma, plasminogen activators, proteolytic enzymes), adapted to concrete characteristics of the coagulation status at different stages of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> formation and permitting the rate of lethal outcomes to be reduced </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> seen in patients with the gravest patterns of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>, <z:chebi fb="5" ids="28304">heparin</z:chebi> may be indicated </plain></SENT>
</text></document>